31784-71-1

Basic information

• Product Name: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE
• Synonyms: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE;5-Chloro-thiazolo[5,4-b]-2-aMinopyridine;5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-aMine
• CAS NO: 31784-71-1
• Molecular Formula: C₆H₄ClN₃S
• Molecular Weight: 185.6341
• Mol File: 31784-71-1.mol

Chemical Properties

• Boiling Point: 356.8 °C at 760 mmHg
• Flash Point: 169.6 °C
• Appearance: /
• Density: 1.632 g/cm³
• Vapor Pressure: 2.85E-05mmHg at 25°C
• Refractive Index: 1.781
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.81±0.40(Predicted)
• CAS DataBase Reference: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE(31784-71-1)
• EPA Substance Registry System: 5-CHLORO-THIAZOLO[5,4-B]PYRIDIN-2-AMINE(31784-71-1)

Safety Data

• Hazardous Substances Data: 31784-71-1(Hazardous Substances Data)

Usage

Uses

5-Chlorothiazolo[5,4-b]pyridin-2-amine

InChI:InChI=1/C6H4ClN3S/c7-4-2-1-3-5(10-4)11-6(8)9-3/h1-2H,(H2,8,9)

Upstream product

• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 333-20-0 potassium thioacyanate 
• 540-72-7 sodium thiocyanide 
• 1050501-88-6 2-bromo-6-chloro-pyridin-3-amine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 62476-56-6 3-amino-2,6-dichloropyridine 
• 131423-80-8 2-benzamido-5-chlorothiazolo<5,4-b>pyridine 
• 505-14-6 thiocyanogen 

Downstream Products

• 1244060-24-9 5-[3-(methylsulfonyl)phenyl][1,3]thiazolo[5,4-b]pyridin-2-amine 
• 1557206-59-3 3-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)-1-(2-{1′-(2,2-dimethylpropyl)-5-fluoro-4-(4-fluorophenyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4′-piperidine]-1-yl}phenyl)urea 
• 1557208-57-7 3-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)-1-(2-{1′-(2,2-dimethylpropyl)-5-fluoro-4-(4-fluorophenyl)-7-methoxy-1,2-dihydrospiro[indole-3,4′-piperidine]-1-yl}phenyl)urea 
• 54459-89-1 5-chloro-[1,2,3]thiadiazolo[5,4-b]pyridine 
• 1617505-26-6 C₃₀H₂₅ClFN₅O₂S 
• 1555697-54-5 3-(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)-1-{2-[4-(4-fluorophenyl)-7-hydroxy-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl]-phenyl}urea 
• 1445884-07-0 C₁₄H₇ClN₄O₂S 
• 1445882-16-5 C₂₆H₃₀N₈O₂S 
• 1445884-24-1 C₁₉H₁₇N₅OS 
• 1445884-23-0 C₁₈H₂₀N₆S 
• 1445884-08-1 C₁₄H₉ClN₄S 
• 1228465-67-5 N-(5-{[4-fluoro-3-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)phenyl]amino}[1,3]thiazolo[5,4-b]pyridin-2-yl)cyclopropanecarboxamide 
• 1228465-66-4 N-(5-{[3-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-4-fluorophenyl]amino}[1,3]thiazolo[5,4-b]pyridin-2-yl)cyclopropanecarboxamide 
• 1125632-90-7 N-{5-[(3-amino-4-fluorophenyl)amino][1,3]thiazolo[5,4-b]pyridin-2-yl}cyclopropanecarboxamide 

Relevant articles and documents

Benzothiazole derivatives and their uses

The present invention relates to benzothiazole derivatives and their uses, specifically to compounds shown in formula I or stereoisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, methods of preparation thereof, and pharmaceutical compositions containing the compounds, wherein the substituentsR1,R2,R8 , X, Y, Z, Q have the meaning given in the instruction manual. The present invention further relates to the application of compounds of formula I in the preparation of drugs for the treatment and / or prevention of sEH-mediated diseases, in particular in the preparation of drugs for the treatment of inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes mellitus, diabetic complications, diabetes-related diseases, fibrotic diseases, neurological and psychiatric diseases, pain, ulcerative diseases and the like.

HERBICIDAL COMPOUNDS

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

NOVEL COMPOUNDS FOR DIAGNOSIS

The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, a- synuclein, A-syn, α-syn, aSyn, SNCA, Non-amyloid beta component of Alzheimer's disease (AD) amyloid plaques, Non-A4 component of amyloid precursor, NACP) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease (PD). The instant compounds are particularly useful in the diagnosis of the preclinical state of such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament.

1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

COMPOUNDS AND METHODS FOR TREATING CANCER

Substituted hydrazone compounds, methods of making such compounds and metal complexes thereof, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds and metal complexes to treat, prevent or ameliorate cancer are provided.

TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF

The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase.

7-HYDROXY-SPIROPIPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of Ρ2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.

Identification of 1-{2-[4-chloro-1′-(2,2-dimethylpropyl)-7-hydroxy-1, 2-dihydrospiro[indole-3,4′-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3] thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y1 antagonist as an antiplatelet agent

Spiropiperidine indoline-substituted diaryl ureas had been identified as antagonists of the P2Y1 receptor. Enhancements in potency were realized through the introduction of a 7-hydroxyl substitution on the spiropiperidinylindoline chemotype. SAR studies were conducted to improve PK and potency, resulting in the identification of compound 3e, a potent, orally bioavailable P2Y1 antagonist with a suitable PK profile in preclinical species. Compound 3e demonstrated a robust antithrombotic effect in vivo and improved bleeding risk profile compared to the P2Y12 antagonist clopidogrel in rat efficacy/bleeding models.

TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF

The present invention relates to a tri-heterocyclic derivatives, preparation process and uses thereof, specifically relates to a tri-heterocyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, preparation process, and further relates to a pharmaceutically acceptable composition comprising compounds of formula (I), or a pharmaceutically acceptable salt thereof, and their pharmaceutical use as inhibitors of kinase